Publications by authors named "S I Sleptsova"
Post-Vaccination and Post-Infection Immunity to the Hepatitis B Virus and Circulation of Immune-Escape Variants in the Russian Federation 20 Years after the Start of Mass Vaccination.
Vaccines (Basel)
February 2023
Article Synopsis
- Russia initiated a neonatal vaccination against Hepatitis B (HBV) 20 years ago, followed by catch-up immunizations for those under 60 starting in 2006, and this study evaluates the immunity and infection rates across different regions.
- Testing of 36,149 volunteers revealed a low HBsAg detection rate of 0.8%, with 2.4% in the Republic of Dagestan, while vaccinated individuals showed less than 0.3% HBsAg detection but a 7.4% rate of ongoing HBV circulation among those under 20 years.
- Despite a stable prevalence of immune-escape HBsAg variants (around 25%), the wild-type HBV population significantly decreased in size
Aim: To study the efficacy and safety of bulevirtide, the HBV and HDV entry inhibitor.
Materials And Methods: Analysis of the results of using bulevirtide in randomized controlled open-label comparative studies MYR202 and MYR203 in 56 patients with chronic hepatitis D and compensated cirrhosis, in monotherapy and combination with pegylated interferon alpha-2a (PEG-IFN).
Results: Monotherapy with bulevirtide for 24 weeks in the MYR202 study in 46 patients with compensated liver cirrhosis demonstrated: 1) a high rate of virological (100%) and biochemical response (alanine aminotransferase normalization rate 45.
Background: Bulevirtide is a first-in-class peptidic entry inhibitor for hepatitis B virus (HBV) and hepatitis D virus infection. In July, 2020, bulevirtide 2 mg received conditional marketing authorisation by the European Medical Agency for treatment of chronic hepatitis D virus infection. We investigated the antiviral activity of bulevirtide in patients chronically infected with HBV and hepatitis D virus.
View Article and Find Full Text PDFBackground: The geographic distribution of the hepatitis B virus (HBV) and the hepatitis D virus (HDV) genotypes is uneven. We reconstructed the temporal evolution of HBV and HDV in Yakutia, one of the regions of Russia most affected by HBV and HDV, in an attempt to understand the possible mechanisms that led to unusual for Russia pattern of viral genotypes and to identify current distribution trends.
Methods: HBV and HDV genotypes were determined in sera collected in 2018-2019 in Yakutia from randomly selected 140 patients with HBV monoinfection and 59 patients with HBV/HDV.
Incidence of socially significant infectious diseases (HIV, TB and HIV/TB coinfection) in the Arctic regions of Russia).
Int J Circumpolar Health
December 2021
The study is aimed to evaluate the HIV, TB, and HIV/TB coinfection incidence per 100,000 population/year in Russian Arctic, based on official statistical data. The epidemics' incidence in Russian Arctic is uneven. The highest HIV incidence in 2019 was registered in Krasnoyarsk region (94,6), and the highest TB incidence in ChAD (136,1).
View Article and Find Full Text PDF